Denali Therapeutics Inc. (DNLI)
$
13.24
-0.30 (-2.27%)
Key metrics
Financial statements
Free cash flow per share
-2.2449
Market cap
1.9 Billion
Price to sales ratio
0
Debt to equity
0.0433
Current ratio
9.5632
Income quality
0.8053
Average inventory
0
ROE
-0.3590
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Denali Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of therapeutic candidates for neurodegenerative diseases based in the United States. The company recorded a notable revenue of $0.00 showcasing its steady growth in a challenging industry. The earnings per share (EPS) is reported at -$2.57 indicating the company's profitability on a per-share basis, despite facing operational challenges. Its operating expenses amount to $501,878,000.00 encompassing various operational costs incurred during development. The EBITDA ratio is 0.00 highlighting the company's operational efficiency in its ongoing and future projects. However, the company reported a net loss of -$422,773,000.00 indicating challenges in its operations as it continues to invest in innovative therapies. Denali offers a range of therapeutic candidates, such as the LRRK2 inhibitor product candidate BIIB122/DNL151, which is currently in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. Additionally, the company is progressing with DNL310 in Phase I/II trials for Hunter syndrome, and DNL343 in phase 1 trials for amyotrophic lateral sclerosis (ALS). Completing a phase I clinical trial, AR443820/DNL788 targets ALS, multiple sclerosis (MS), and Alzheimer's disease, while SAR443122/DNL758 is in phase II trials for cutaneous lupus erythematosus. The company collaborates with notable partners including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, and the Michael J. Fox Foundation, among others, to enhance its research and development efforts. In the financial landscape, the stock is affordable at $13.54 suitable for budget-conscious investors looking to enter the biopharmaceutical market. It has an average trading volume of 1,477,268.00 indicating moderate liquidity, which may appeal to a broad range of investors. With a mid-range market capitalization of $1,923,454,240.00 the company is a steady performer that plays an essential role in the biopharmaceutical industry, contributing significantly to the overall market landscape. Denali Therapeutics belongs to the Healthcare sector, driving innovation and growth, underscoring its commitment to addressing unmet medical needs in neurodegenerative diseases and beyond.
Is Denali Therapeutics Inc. (DNLI) a good investment?
Investing in Denali Therapeutics Inc. (DNLI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Denali Therapeutics Inc. (DNLI)'s stock forecast?
Analysts predict Denali Therapeutics Inc. stock to fluctuate between $10.57 (low) and $33.33 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Denali Therapeutics Inc.'s market capitalization?
As of 2025-05-30, Denali Therapeutics Inc.'s market cap is $1,923,454,240, based on 145,276,000 outstanding shares.
How does Denali Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Denali Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Denali Therapeutics Inc. (DNLI) stock?
To buy Denali Therapeutics Inc. (DNLI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNLI. Place an order (Market, Limit, etc.).
What is the best time to invest in Denali Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Denali Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.57 | Growth: 142.45%.
Where can I find Denali Therapeutics Inc.'s investor relations reports?
Visit https://www.denalitherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Denali Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Denali Therapeutics Inc. stock?
All-time high: $79.70 (2021-06-30) | All-time low: $10.57 (2025-04-07).
What are the key trends affecting Denali Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
24 days ago
DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA?
globenewswire.com
25 days ago
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights.
zacks.com
a month ago
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
zacks.com
2 months ago
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
globenewswire.com
2 months ago
SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the company's initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II) has been received by the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA). Denali continues to have regular, collaborative, and productive engagement with CDER and is aligned with CDER on the content of the BLA data package, including the use of cerebrospinal fluid heparan sulfate (CSF HS) as a surrogate endpoint to support an accelerated approval, as well as the full approval conversion path. Denali expects to complete the BLA submission in the first half of May 2025 and continues to prepare for a potential commercial launch in the U.S. in late 2025 or early 2026.
seekingalpha.com
2 months ago
Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson's Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact.
zacks.com
2 months ago
Denali (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
zacks.com
3 months ago
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
globenewswire.com
3 months ago
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights.
zacks.com
4 months ago
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational therapy, tividenofusp alfa.
See all news
